OA12925A - Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. - Google Patents
Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. Download PDFInfo
- Publication number
- OA12925A OA12925A OA1200500074A OA1200500074A OA12925A OA 12925 A OA12925 A OA 12925A OA 1200500074 A OA1200500074 A OA 1200500074A OA 1200500074 A OA1200500074 A OA 1200500074A OA 12925 A OA12925 A OA 12925A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- crc6
- compound
- phenyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41213102P | 2002-09-18 | 2002-09-18 | |
| US48458003P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12925A true OA12925A (en) | 2006-10-13 |
Family
ID=32033584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200500074A OA12925A (en) | 2002-09-18 | 2003-09-12 | Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7030125B2 (de) |
| EP (1) | EP1542995A1 (de) |
| JP (1) | JP2006506443A (de) |
| KR (1) | KR20050057441A (de) |
| CN (1) | CN1681809A (de) |
| AP (1) | AP2005003262A0 (de) |
| AR (1) | AR041275A1 (de) |
| AU (1) | AU2003263431A1 (de) |
| BR (1) | BR0314286A (de) |
| CA (1) | CA2499332A1 (de) |
| CO (1) | CO5550458A2 (de) |
| EA (1) | EA200500286A1 (de) |
| EC (1) | ECSP055685A (de) |
| HR (1) | HRP20050246A2 (de) |
| IS (1) | IS7695A (de) |
| MA (1) | MA27444A1 (de) |
| MX (1) | MXPA05002378A (de) |
| NO (1) | NO20051852L (de) |
| OA (1) | OA12925A (de) |
| PA (1) | PA8583101A1 (de) |
| PE (1) | PE20050076A1 (de) |
| PL (1) | PL375973A1 (de) |
| TW (1) | TW200410954A (de) |
| UY (1) | UY27983A1 (de) |
| WO (1) | WO2004026865A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2323421T3 (es) | 2002-09-18 | 2009-07-15 | Pfizer Products Inc. | Nuevos compuestos de oxazol como inhibidores del factor de crecimientotransformador (tgf). |
| EA200500378A1 (ru) * | 2002-09-18 | 2005-08-25 | Пфайзер Продактс Инк. | Новые соединения имидазола в качестве ингибиторов трансформирующего фактора роста (tgf) |
| MXPA05002376A (es) | 2002-09-18 | 2005-05-23 | Pfizer Prod Inc | Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf). |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| EP1799668A1 (de) | 2004-09-20 | 2007-06-27 | Xenon Pharmaceuticals Inc. | Heterozyklische derivate und ihre verwendung als stearoyl-coa-desaturase-mediatoren |
| JP5043668B2 (ja) | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| US7919496B2 (en) | 2004-09-20 | 2011-04-05 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes |
| BRPI0515489A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase |
| BRPI0515500A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados piridazina para inibição de estearoil-coa-desaturase |
| AR051092A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa |
| AU2005329423A1 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
| BRPI0607688A2 (pt) * | 2005-02-17 | 2009-09-22 | Synta Pharmaceuticals Corp | método para inibir a polimerização de tubulina em uma célula; método para tratar ou prevenir um distúrbio proliferativo em um indivìduo; método para bloquear, ocluir ou de outro modo romper o fluxo sangüìneo na neovasculatura; composto; composição farmacêutica e uso do referido método e composto |
| CN101208089A (zh) | 2005-06-03 | 2008-06-25 | 泽农医药公司 | 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂 |
| KR20080082618A (ko) * | 2005-12-16 | 2008-09-11 | 알콘, 인코퍼레이티드 | Ａｌｋ5 조절제를 사용한 안압의 조절 |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| PT2970890T (pt) | 2013-03-14 | 2020-04-24 | Massachusetts Inst Technology | Composições e métodos para expansão e cultura de células estaminais epiteliais |
| ES2813875T3 (es) | 2014-01-01 | 2021-03-25 | Medivation Tech Llc | Compuestos y procedimientos de uso |
| JP6773645B2 (ja) | 2014-09-03 | 2020-10-21 | ザ ブリガム アンド ウィミンズ ホスピタル，インコーポレイテッド | 聴覚障害の治療のための内耳毛細胞を生成するための組成物、システムおよび方法 |
| EP3313420B1 (de) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Verfahren und zusammensetzungen in bezug auf hämatopoetische stammzellenexpansion, -anreicherung und -pflege |
| AU2017205194A1 (en) | 2016-01-08 | 2018-07-19 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| JP7080179B2 (ja) | 2016-03-15 | 2022-06-03 | ザ チルドレンズ メディカル センター コーポレーション | 造血幹細胞の増大に関する方法および組成物 |
| BR112019013388A2 (pt) | 2016-12-30 | 2020-03-03 | Frequency Therapeutics, Inc. | Compostos de 1h-pirrol-2,5-diona e métodos de uso dos mesmos para induzir a autorrenovação de células de suporte tronco/progenitoras |
| CN112135613A (zh) | 2018-03-20 | 2020-12-25 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| WO2019236766A1 (en) | 2018-06-06 | 2019-12-12 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
| WO2020037323A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| WO2020037326A1 (en) | 2018-08-17 | 2020-02-20 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating foxo |
| US20220162182A1 (en) | 2018-12-31 | 2022-05-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5095272A (de) * | 1973-12-24 | 1975-07-29 | ||
| AU7726898A (en) | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
| EP0983260A2 (de) | 1997-05-22 | 2000-03-08 | G.D. Searle & Co. | 4-aryl-3 (5)-heteroaryl substituierte pyrazole als inhibitoren der p38 kinase |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| EP1169317B1 (de) | 1999-04-09 | 2003-01-15 | SmithKline Beecham Corporation | Triarylimidazole |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| AU2002225730A1 (en) | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
| GB0027987D0 (en) * | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| GB0102672D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| JP2004521901A (ja) * | 2001-02-02 | 2004-07-22 | グラクソ グループ リミテッド | Ｔｇｆ阻害剤としてのピラゾール |
| GB0102668D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| US20040087623A1 (en) * | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
| US6673818B2 (en) * | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| AR040726A1 (es) | 2002-07-31 | 2005-04-20 | Smithkline Beecham Corp | Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento |
-
2003
- 2003-09-12 CN CNA038222043A patent/CN1681809A/zh active Pending
- 2003-09-12 PL PL03375973A patent/PL375973A1/xx not_active Application Discontinuation
- 2003-09-12 AU AU2003263431A patent/AU2003263431A1/en not_active Abandoned
- 2003-09-12 MX MXPA05002378A patent/MXPA05002378A/es active IP Right Grant
- 2003-09-12 AP AP2005003262A patent/AP2005003262A0/xx unknown
- 2003-09-12 OA OA1200500074A patent/OA12925A/en unknown
- 2003-09-12 EA EA200500286A patent/EA200500286A1/ru unknown
- 2003-09-12 WO PCT/IB2003/004005 patent/WO2004026865A1/en active Application Filing
- 2003-09-12 KR KR1020057004662A patent/KR20050057441A/ko not_active Application Discontinuation
- 2003-09-12 BR BR0314286-8A patent/BR0314286A/pt not_active IP Right Cessation
- 2003-09-12 JP JP2004568905A patent/JP2006506443A/ja not_active Withdrawn
- 2003-09-12 CA CA002499332A patent/CA2499332A1/en not_active Abandoned
- 2003-09-12 EP EP03797466A patent/EP1542995A1/de not_active Withdrawn
- 2003-09-15 TW TW092125380A patent/TW200410954A/zh unknown
- 2003-09-16 AR ARP030103359A patent/AR041275A1/es unknown
- 2003-09-16 UY UY27983A patent/UY27983A1/es not_active Application Discontinuation
- 2003-09-17 US US10/667,167 patent/US7030125B2/en not_active Expired - Fee Related
- 2003-09-17 PE PE2003000951A patent/PE20050076A1/es not_active Application Discontinuation
- 2003-09-17 PA PA20038583101A patent/PA8583101A1/es unknown
-
2005
- 2005-02-14 IS IS7695A patent/IS7695A/is unknown
- 2005-03-16 HR HR20050246A patent/HRP20050246A2/hr not_active Application Discontinuation
- 2005-03-17 EC EC2005005685A patent/ECSP055685A/es unknown
- 2005-03-18 CO CO05025189A patent/CO5550458A2/es not_active Application Discontinuation
- 2005-03-18 MA MA28158A patent/MA27444A1/fr unknown
- 2005-04-15 NO NO20051852A patent/NO20051852L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004026865A1 (en) | 2004-04-01 |
| UY27983A1 (es) | 2004-04-30 |
| AR041275A1 (es) | 2005-05-11 |
| MXPA05002378A (es) | 2005-05-23 |
| NO20051852L (no) | 2005-06-16 |
| ECSP055685A (es) | 2005-05-30 |
| EP1542995A1 (de) | 2005-06-22 |
| AU2003263431A1 (en) | 2004-04-08 |
| US20040116473A1 (en) | 2004-06-17 |
| US7030125B2 (en) | 2006-04-18 |
| IS7695A (is) | 2005-02-14 |
| TW200410954A (en) | 2004-07-01 |
| MA27444A1 (fr) | 2005-07-01 |
| CO5550458A2 (es) | 2005-08-31 |
| PL375973A1 (en) | 2005-12-12 |
| PA8583101A1 (es) | 2004-04-23 |
| KR20050057441A (ko) | 2005-06-16 |
| CA2499332A1 (en) | 2004-04-01 |
| BR0314286A (pt) | 2005-08-02 |
| PE20050076A1 (es) | 2005-03-26 |
| AP2005003262A0 (en) | 2005-03-31 |
| CN1681809A (zh) | 2005-10-12 |
| HRP20050246A2 (en) | 2005-10-31 |
| JP2006506443A (ja) | 2006-02-23 |
| EA200500286A1 (ru) | 2005-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA12925A (en) | Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. | |
| US7053095B2 (en) | Triazole compounds as transforming growth factor (TGF) inhibitors | |
| US7151110B2 (en) | Pyrazole compounds as transforming growth factor (TGF) inhibitors | |
| US7199123B2 (en) | Pyrazine compounds as transforming growth factor (TGF) compounds | |
| EP1542990B1 (de) | Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf) | |
| US20040176390A1 (en) | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors | |
| ZA200502277B (en) | Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. |